Pharmacotherapy of chronic kidney disease and mineral bone disorder

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2627-2640

  Barreto, Fellype Carvalho ^a   De Oliveira, Rodrigo Azevedo ^a   Oliveira, Rodrigo Bueno ^a   Jorgetti, Vanda ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Calcimimetic; Calcium; Chronic kidney disease; CKD MBD; Parathormone; Phosphate binders; Phosphorus; Renal osteodystrophy; Vitamin D; Vitamin D receptor activators

Indexed keywords

25 HYDROXYVITAMIN D; ALUMINUM HYDROXIDE; ATORVASTATIN; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CHITOSAN; CINACALCET; COLECALCIFEROL; COLESTILAN; DOXERCALCIFEROL; ERGOCALCIFEROL; FERMAGATE; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; NICOTINAMIDE; NICOTINIC ACID; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; VITAMIN D RECEPTOR;

ACIDOSIS; ADJUVANT THERAPY; ALUMINUM OVERLOAD; ANEMIA; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MINERALIZATION; BONE REMODELING; BRAIN DISEASE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEMENTIA; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; HEMODIALYSIS; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATASEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY FAILURE; MICROCYTIC ANEMIA; MINERAL METABOLISM; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; OSTEOLYSIS; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PREVALENCE; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIMIMETIC AGENTS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; PHOSPHORUS; VITAMIN D;

EID: 81255195244     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.626768     Document Type: Review

References (119)

1. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
2. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
3. CKD-MBD Work Group. Kidney disease: improving global outcomes (KDIGO). KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-130
4. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
5. Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96
6. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14:S300-4
7. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of deathand cardiovascular disease in individuals with chronic kidney disease. JAMA 2011;305:1119-27
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
9. Mathewson AM, Fouque D, Toft AJ. Dietary phosphate assessment in dialysis patients. J Ren Nutr 2010;20:351-8
10. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998;53:1399-404
11. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005;16:2778-88
12. Salusky IB. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl 2006;105:S10-15
13. Mudge DW, Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011;12:20
14. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-24
15. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102
16. Almirall J, Veciana L, Llibre J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am J Nephrol 1994;14:192-6
17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
18. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994;46:855-61
19. Spiegel DM. Magnesium in chronic kidney disease: unanswered questions. Blood Purif 2011;31:172-6
20. Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int 1996;49:163-7
21. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987;32:388-94
22. Tomazic B, Tomson M, Nancollas GH. Growth of calcium phosphates on hydroxyapatite crystals: the effect of magnesium. Arch Oral Biol 1975;20:803-8
23. Gonella M, Ballanti P, Della Rocca C, et al. Improved bone morphology by normalizing serum magnesium in chronically hemodialyzed patients. Miner Electrolyte Metab 1988;14:240-5
24. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006;1:697-703
25. Barreto DV, Barreto F de C, de Carvalho AB, et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008;110:c273-83
26. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
27. Ferreira A, Frazao JM, Monier-Faugere M-C, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008;19:405-12
28. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61
29. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
30. Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer onprogression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
31. Oliveira RB, Cancela ALE, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-91
32. Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism inchronic kidney disease. Kidney Int 2009;76:705-16
33. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92
34. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011;26:2567-71
35. Kobayashi K, Imanishi Y, Miyauchi A, et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006;154:93-9
36. Koizumi M, Komaba H, Nakanishi S, et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2011;published online 5 july 2011; doi:10.1093/ndt/ gfr384.
37. de Freitas D, Donne RL, Hutchison AJ. Lanthanum carbonate - a first line phosphate binder? Semin Dial 2007;20:325-8
38. Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol 2006;1:704-9
39. Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009;29:554-61
40. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102:c61-71
41. Drueke TB. Lanthanum carbonate as a first-line phosphate binder: the "cons". Semin Dial 2007;20:329-32
42. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68:2809-13
43. Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110:c15-23
44. Pennick M, Dennis K, Damment SJP. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006;46:738-46
45. Malluche HH, Siami GA, Swanepoel C, et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008;70:284-95
46. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005;64:428-37
47. Fraile P, Cacharro LM, Garcia-Cosmes P, et al. Encephalopathy caused by lanthanum carbonate. NDT Plus 2011;4:192-4
48. Savica V, Calo LA, Monardo P, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 2009;20:639-44
49. Berns JS. Niacin and related compounds for treating hyperphosphatemia in dialysis patients. Semin Dial 2008;21:203-5
50. Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
51. Muller D, Mehling H, Otto B, et al. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2007;2:1249-54
52. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004;24:503-10
53. Unger MD, Cuppari L, Titan SM, et al. Vitamin D status in a sunny country: where has the sun gone? Clin Nutr 2010;29:784-8
54. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1128-35
55. Al-Aly Z, Qazi RA, Gonzalez EA, et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007;50:59-68
56. DeVille J, Thorp ML, Tobin L, et al. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 2006;11:555-9
57. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007;27:36-43
58. Jean G, Terrat J-C, Vanel T, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 2008;23:3670-6
59. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010;5:905-11
60. Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007;105:c132-8
61. Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43
62. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;96:1786-93
63. Naveh-Many T, Marx R, Keshet E, et al. Regulation of 1,25- dihydroxyvitaminD3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 1990;86:1968-75
64. Delmez JA, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-55
65. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160-6
66. Levine BS, Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 1996;7:488-96
67. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994;45:1710-21
68. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-51
69. Frazao JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;36:550-61
70. Coburn JW, Maung HM, Elangovan L, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-90
71. Tan AU Jr, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23
72. Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011;79:112-19
73. Maung HM, Elangovan L, Frazao JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D (2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-43
74. Weber K, Goldberg M, Stangassinger M, Erben RG. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats. J Bone Miner Res 2001;16:639-51
75. Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-23
76. Martin KJ, Gonzalez EA, Gellens M, et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-32
77. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38(5 Suppl 5):S45-50
78. Takahashi F, Finch JL, Denda M, et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105-12
79. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor- 1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279-84
80. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxyvitamin D3 and 19-nor-1,25-dihydroxyvitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999;10:980-5
81. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
82. Monier-Faugere M-C, Mawad H, Malluche HH. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal- parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1255-60
83. Martin KJ, Gonzalez E, Lindberg JS, et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 2001;38:S57-63
84. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
85. Mittman N, Desiraju B, Meyer KB, et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl 2010;117:S33-6
86. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6
87. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-15
88. Becker LE, Koleganova N, Piecha G, et al. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2011;300:F772-82
89. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008;19:1613-19
90. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-8
91. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-65
92. Wu-Wong JR, Kawai M, Chen Y-W, Nakane M. VS-105: a novel VDR modulator with cardiovascular protective effects. Br J Pharmacol 2011;published online 28 august 2011; doi: 10.1111/j.1476-5381.2011.01473.x.
93. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80
94. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-5
95. Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24
96. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-54
97. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
98. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
99. Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
100. Urena P, Jacobson SH, Zitt E, et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice-the ECHO observational study. Nephrol Dial Transplant 2009;24:2852-9
101. Wada M. The calcimimetic compound AMG 073 (cinacalcete HCl) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol 2003;14(48A):abstract SU-FC218
102. Malluche HH, Monier-Faugere M-C, Wang G, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008;69:269-78
103. Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24:982-9
104. Sumida K, Nakamura M, Ubara Y, et al. Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 2011;published online 12 May 2011; doi: 10.1136/jclinpath-2011-200100.
105. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-00
106. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010;78:578-89
107. Brancaccio D, Cozzolino M, Cannella G, et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 2011;32:124-32
108. Ivanovski O, Nikolov IG, Joki N, et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009;205:55-62
109. Koleganova N, Piecha G, Ritz E, et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009;75:60-71
110. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39
111. Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58-67
112. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 2009;53:197-207
113. Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1315-19
114. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20:1311-14
115. Schwarz A, Merkel S, Leitolf H, Haller H. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation 2011;91:560-5
116. Cho ME, Duan Z, Chamberlain CE, et al. Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplant Proc 2010;42:3554-8
117. Carrasco FR, Perez-Flores I, Calvo N, et al. Treatment of persistent hyperparathyroidism in renal transplant patients with cinacalcet improves control of blood pressure. Transplant Proc 2009;41:2385-7
118. Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009;4:1465-76
119. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7